PD-L1 is the major target of ICIs, and PD-L1 expression assessed using immunohistochemistry (IHC) is considered a predictive biomarker for response to ICIs in NSCLC [1, 3, 7, 9, 11, 12] and other cancers such as gastric cancer [13]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.